Neuropeptides & Cognitive Enhancement: Complete Research Guide

Neuropeptides are a diverse class of peptides produced by and acting on the nervous system to regulate neuronal communication, plasticity, and function. This guide explores the neurobiology of cognition-enhancing peptides, BDNF signalling, and research applications in neuroprotection and cognitive enhancement.

What Are Neuropeptides? Neuropeptides are signalling molecules in the brain and peripheral nervous system, distinct from classical neurotransmitters (dopamine, serotonin, acetylcholine). Key characteristics:

Synthesis: Produced by neurons and other cells in response to various stimuli
Release: Often co-released with classical neurotransmitters
Receptors: Act on specific G-protein coupled receptors or receptor tyrosine kinases
Duration: Longer-acting than classical neurotransmitters (minutes to hours vs. milliseconds)
Function: Neuromodulation, neuroprotection, plasticity, cognition

Key Neuropeptide Classes:

Nootropic Peptides (cognitive enhancers): Semax, Selank, Dihexa
BDNF-Upregulating Peptides: Semax, Selank, Colivelin
Sleep-Regulating Peptides: DSIP, Orexin, Melatonin
Stress-Response Peptides: Selank (anxiolytic), Semax (stress-protective)
Neuroprotective Peptides: Colivelin, Dihexa, Orexin

BDNF: The Master Molecule Brain-Derived Neurotrophic Factor is a critical neurotrophin (nerve growth-promoting protein) that:

Supports neuronal survival and growth
Enhances synaptic plasticity (learning capacity)
Promotes long-term potentiation (LTP) — memory consolidation
Increases neurogenesis (new neuron formation)
Reduces neuroinflammation
Protects against neurodegeneration

Many neuropeptides work by upregulating BDNF, explaining their cognitive benefits.

Why Neuropeptides Matter in Research Understanding neuropeptides is critical for:

Cognitive enhancement and learning acceleration
Neurodegeneration prevention (Alzheimer’s, Parkinson’s)
Stress and anxiety reduction
Depression and mood disorders
Brain aging and longevity
Neuroplasticity and synaptic remodelling
Recovery from brain injury

History & Discovery

Early Neuropeptide Research Neuropeptides were discovered in the 1970s when researchers identified opioid-like peptides (endorphins) in the brain. This led to systematic identification of other neuromodulatory peptides.

Russian Peptide Research Much nootropic peptide research originated in Soviet Union/Russia:

Semax: Developed in 1980s at Russian Academy of Medical Sciences, derived from ACTH fragment
Selank: Developed concurrently, modified ACTH-derived peptide
DSIP: Discovered as “sleep-inducing peptide” in 1970s

Key Milestones:

1970s: Endorphins discovered; opioid peptides identified
1980s: Semax and Selank development (USSR)
1990s: BDNF identified as critical neurotrophin; neurogenesis discovered in adult brain
2000s: Understanding of neuropeptide-BDNF interactions expands
2010s: Advanced brain imaging reveals neuropeptide network complexity
2020s: Neuropeptide research accelerates; clinical trials begin for cognitive enhancement

Soviet Legacy Russian research community produced some of the most innovative neuropeptide compounds. While less well-known in Western literature, these peptides have decades of research supporting their efficacy.

Mechanism of Action

BDNF Signalling Cascade

BDNF binds to TrkB (tropomyosin receptor kinase B), a receptor tyrosine kinase, triggering:

TrkB Activation:
- BDNF binding causes TrkB receptor dimerisation
- Autophosphorylation of intracellular tyrosine residues
- Recruitment of signalling proteins
PI3K/Akt Pathway:
- Phospholipid kinase 3 (PI3K) activation
- Akt (protein kinase B) phosphorylation
- Promotes cell survival, growth, protein synthesis
- Activates mTOR → enhanced translation
- Anti-apoptotic effects (prevents cell death)
MAPK/ERK Pathway:
- Mitogen-activated protein kinase cascade
- ERK1/2 (extracellular signal-regulated kinases) phosphorylation
- Gene transcription changes
- Promotes cell proliferation and differentiation
CREB Activation:
- cAMP response element binding protein
- Phosphorylated by multiple kinases downstream of TrkB
- Translocates to nucleus
- Activates genes for neuronal growth, BDNF itself (positive feedback), and neuroprotection

BDNF Feedback Loop Critically, BDNF activates its own expression via CREB (positive feedback), meaning:

Initial BDNF upregulation from neuropeptides amplifies over time
Sustained elevation persists even after peptide clearance
This explains long-term cognitive benefits from short-term peptide exposure

Semax Mechanism (Example Neuropeptide)

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic ACTH fragment with multiple mechanisms:

BDNF Upregulation:
- Direct transcriptional enhancement of BDNF
- Activates CREB via multiple pathways
- Result: ↑ BDNF mRNA, ↑ BDNF protein levels
Monoamine Modulation:
- ↑ Dopamine synthesis and release (motivation, focus)
- ↑ Noradrenaline (attention, arousal)
- ↓ Serotonin reuptake (mood improvement)
- Net: Enhanced arousal, focus, mood
Neuroprotection:
- ↓ Glutamate excitotoxicity (reduces neurotoxic calcium influx)
- ↓ Neuroinflammation (reduced IL-6, TNF-α)
- ↑ Antioxidant defence (SOD, catalase expression)
- Result: Protection against neurodegeneration, ischemia, toxins
Neurogenesis Enhancement:
- Promotes proliferation of neural progenitor cells
- Enhances differentiation into mature neurons
- Increases neurogenesis in hippocampus (memory formation)
- BDNF-dependent and independent mechanisms

Selank Mechanism (Complementary Anxiolytic)

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) has overlapping but distinct mechanisms:

BDNF Upregulation (like Semax, but through different pathways):
- ↑ BDNF in hippocampus and prefrontal cortex
- Enhanced synaptic plasticity
GABAergic Enhancement (distinct from Semax):
- ↑ GABA synthesis and release
- Enhanced GABA receptor sensitivity
- Anxiolytic effect (calming, anti-anxiety)
- Result: Reduced anxiety while maintaining cognition
Stress-Protective Effects:
- ↓ Cortisol dysregulation (HPA axis normalisation)
- ↓ Anxiety-related amygdala hyperactivity
- ↑ Prefrontal cortex function (emotional regulation)
Immune-Neuroendocrine Interactions:
- ↑ Immune regulation
- ↓ Chronic inflammation
- Result: Stress resilience, mood stability

Colivelin: STAT3 Activation Model

Colivelin has a distinct mechanism centred on STAT3:

STAT3 Pathway Activation:
- Direct or indirect STAT3 (signal transducer and activator) activation
- STAT3 phosphorylation and nuclear translocation
- Activates neuroprotective genes
- Distinct from BDNF-TrkB pathway
Neuroprotection:
- Promotes neuron survival in degeneration models (Alzheimer’s, Parkinson’s)
- ↑ Neurotrophic factors beyond BDNF
- ↓ Neuroinflammation
Synergy with BDNF:
- STAT3 and TrkB signalling complement each other
- Colivelin + BDNF-enhancing peptides (Semax, Selank) may be synergistic

Biochemistry & Structure

Semax Sequence

Met-Glu-His-Phe-Pro-Gly-Pro

Length: 7 amino acids (heptapeptide)
MW: 813.9 g/mol
CAS: 80714-61-0
Structure: Simple linear peptide; highly stable
Modification: Derived from ACTH(4–10) fragment
Bioavailability: Intranasal preferred route (BBB penetration); also SC/IM

Selank Sequence

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Length: 7 amino acids (heptapeptide)
MW: 751.9 g/mol
CAS: 129954-34-3
Structure: Similar to Semax but distinct amino acids
Modification: Derived from ACTH(4–10), similar origin but different sequence
Bioavailability: Intranasal preferred; SC/IM also effective

DSIP (Delta Sleep-Inducing Peptide) Sequence

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

Length: 9 amino acids (nonapeptide)
MW: 828.8 g/mol
CAS: 62568-57-4
Structure: More complex; naturally occurring sleep peptide
Function: Sleep regulation, neuroendocrine modulation
Bioavailability: Primarily intranasal; SC/IM possible

Dihexa Sequence

N-4-hydroxyphenylethyl, N4-[L-(-)-prolyl]

(Simplified; complex structure)

Length: Dipeptide with modified sidechain
MW: 488.6 g/mol
CAS: 1401708-83-5
Modification: Highly modified; synthetic compound
Target: HGF/c-Met receptor pathway
Bioavailability: Can cross blood–brain barrier efficiently

Colivelin Sequence (partial)

Asp-Ala-Gly-Ile-Leu-Asp-Ser-Leu-Lys...

(Multi-domain structure)

Length: Complex; ~109 amino acids in modified form
MW: 2,553.8 g/mol
CAS: 799279-67-7
Structure: Derived from interleukin-6; complex domains
Target: STAT3 and related pathways
Bioavailability: Requires injection (SC/IV)

Research Applications

Primary Applications:

A. Cognitive Enhancement & Memory

Spatial learning and memory consolidation (hippocampal LTP)
Working memory capacity improvement
Processing speed and reaction time
Attention and focus (sustained, selective)
Learning acceleration and retention
Recall speed and accuracy

B. Neuroprotection & Neurodegeneration

Alzheimer’s disease models (tau pathology, amyloid clearance)
Parkinson’s disease models (dopaminergic neuron protection)
Stroke and ischemia recovery
Neuroinflammation reduction (microglia activation)
Glutamate excitotoxicity prevention
Age-related neurodegeneration

C. Stress & Anxiety Reduction

Acute stress response modulation
Chronic stress resilience
Anxiety disorder models (PTSD, GAD-like)
HPA axis normalisation
Amygdala hyperactivity reduction
Mood and emotional regulation

D. Neurogenesis & Plasticity

Neural stem cell proliferation
Neurogenesis in hippocampus (adult neurogenesis)
Synaptogenesis (new synapse formation)
Synaptic plasticity (LTP, long-term depression)
Dendritic spine density
Circuit remodelling after learning

E. Sleep & Circadian Rhythm

Sleep quality and architecture (DSIP focus)
Sleep-wake cycle regulation (Orexin focus)
Circadian rhythm entrainment
Sleep spindle frequency (memory consolidation)
REM sleep proportion

F. Depression & Mood Disorders

Depressive symptom reduction (animal models)
BDNF upregulation (antidepressant mechanism)
Monoamine system modulation
HPA axis stress dysregulation
Mood stabilisation

G. Neurological Recovery

Traumatic brain injury (TBI) recovery
Spinal cord injury regeneration
Stroke recovery and neuroplasticity
Paresis and motor function restoration
Cognitive rehabilitation

H. Longevity & Brain Aging

Brain aging slowdown
Age-related cognitive decline prevention
Neuroprotection against age-related pathology
Neuroplasticity maintenance with age
Healthspan extension (cognitive domain)

Key Specifications Table

Property	Semax	Selank	DSIP	Colivelin	Dihexa
Structure	7-aa ACTH fragment	7-aa ACTH-derived	9-aa natural peptide	Modified IL-6 domain	Modified dipeptide
MW	813.9 g/mol	751.9 g/mol	828.8 g/mol	2,553.8 g/mol	488.6 g/mol
Primary Mechanism	BDNF ↑, monoamines	BDNF ↑, GABAergic	Sleep regulation, stress	STAT3 pathway	HGF/c-Met pathway
Primary Effect	Cognitive enhancement	Anxiolytic + cognitive	Sleep-inducing	Neuroprotection	Cognitive enhancement
Route	Intranasal preferred	Intranasal preferred	Intranasal or SC	SC/IV injection	Intranasal or SC
Half-Life	~30 min (intranasal BBB penetration)	~30 min	Unknown (varies)	Moderate	Short
Brain Penetration	Excellent (intranasal)	Excellent (intranasal)	Good	Moderate	Excellent
Stimulation Level	Moderate-High	Low (anxiolytic)	None (calming)	Mild	Moderate
Anxiety Effect	Neutral/mild	↓ Anxiety (major)	↓ Anxiety	Neutral/protective	Neutral
Typical Dose	0.1–0.5 mg/kg/day	0.1–0.5 mg/kg/day	0.2–0.5 mg/kg	0.1–0.5 mg/kg	0.01–0.1 mg/kg

Comparison with Similar Peptides

Semax vs. Selank: Complementary Nootropics

Semax: More stimulating, dopamine-enhancing, focus-promoting
Selank: More anxiolytic, GABAergic, calming but still cognitive-supporting
Combination: Many researchers use both — complementary effects (focus + calm)
Timing: Semax for daytime cognition; Selank for evening/stress

Semax/Selank vs. Pharmaceutical Nootropics

Peptides: Mechanism of action via BDNF; longer-lasting effects after discontinuation
Racetams (piracetam): Direct membrane effects; acute only
Stimulants (amphetamine, methylphenidate): Acute dopamine release; potential dependence
SSRIs (antidepressants): Serotonin reuptake; long-term effects but side effects
Peptide Advantage: BDNF upregulation persists; minimal acute side effects

DSIP vs. Melatonin vs. Orexin

DSIP: Neuroendocrine sleep regulation; also has stress-protective effects
Melatonin: Circadian hormone; more about timing than total sleep drive
Orexin: Wakefulness-promoting; opposite of DSIP
Combination: Possible stacking depending on sleep goal

Colivelin vs. GDNF: Different Mechanisms

Colivelin: STAT3-dependent neuroprotection
GDNF (Glial-Derived Neurotrophic Factor): Direct neurotrophin; different pathway
Synergy: Potentially additive for robust neuroprotection
Research Context: Choose based on mechanistic goals

Products We Carry

Semax

5mg, 10mg vials
Purity: >98%
Form: Lyophilised powder
CAS: 80714-61-0
MW: 813.9 g/mol
Research applications: Cognitive enhancement, BDNF upregulation, neuroprotection, monoamine modulation

Selank

5mg, 10mg vials
Purity: >98%
Form: Lyophilised powder
CAS: 129954-34-3
MW: 751.9 g/mol
Research applications: Anxiolytic, BDNF enhancement, stress resilience, mood support

DSIP (Delta Sleep-Inducing Peptide)

5mg vials
Purity: >98%
Form: Lyophilised powder
CAS: 62568-57-4
MW: 828.8 g/mol
Research applications: Sleep regulation, neuroendocrine modulation, stress response

Colivelin

10mg vials
Purity: >98%
Form: Lyophilised powder
CAS: 799279-67-7
MW: 2,553.8 g/mol
Research applications: Neuroprotection, STAT3 pathway, neurodegeneration models, cognitive support

Dihexa

10mg vials
Purity: >98%
Form: Lyophilised powder
CAS: 1401708-83-5
MW: 488.6 g/mol
Research applications: HGF/c-Met signalling, cognitive enhancement, synaptogenesis, memory

Orexin A & B

5mg vials (each)
Purity: >98%
Form: Lyophilised powder
MW: 3,561 g/mol (Orexin A), 2,685 g/mol (Orexin B)
Research applications: Wakefulness, arousal, feeding behaviour, sleep-wake cycle

Frequently Asked Questions

Q: What’s the difference between Semax and Selank? A: Both are ACTH-derived neuropeptides that upregulate BDNF, but they differ: Semax is more stimulating and dopamine-enhancing (better for focus, daytime use), while Selank is anxiolytic and GABAergic (better for anxiety reduction, calming, evening use). Many researchers use both synergistically.

Q: How long do neuropeptide effects last after stopping? A: BDNF effects tend to persist for weeks to months after discontinuation because BDNF upregulation creates a positive feedback loop (BDNF activates CREB, which further activates BDNF). Short-term cognitive improvements may fade faster, but neuroprotection and plasticity improvements persist.

Q: Can I combine Semax and Selank? A: Yes, and many researchers do. The combination provides both cognitive enhancement (Semax) and anxiolytic support (Selank), capturing complementary benefits. Some prefer Semax in morning, Selank in evening for optimal effects.

Q: Is DSIP good for sleep quality or just sleep induction? A: DSIP improves sleep architecture (structure), not just duration. It increases sleep spindle frequency and REM sleep proportion, which are markers of quality sleep and memory consolidation. It also has stress-protective and neuroendocrine benefits beyond sleep.

Q: How does Colivelin differ from other neuropeptides? A: Colivelin acts primarily via STAT3 pathway (distinct from BDNF-TrkB). This gives it a different mechanistic angle for neuroprotection, particularly in neurodegeneration models. It’s a complementary option rather than replacement for BDNF-upregulating peptides.

Q: What’s the best route of administration for neuropeptides? A: Intranasal is preferred for Semax and Selank because it allows direct CNS penetration via olfactory bulb pathways, bypassing blood–brain barrier limitations. This requires lower doses and provides faster effects. SC/IM are also effective but slower. IV is used in clinical settings.

Q: Are neuropeptides safe for long-term use? A: Neuropeptides have excellent safety profiles in research and clinical use over decades (especially Russian research on Semax/Selank). Side effects are minimal and tolerance is rare. However, as with any research compound, proper dosing and protocols within approved studies are essential.

Related Research & External Links

Key Research Areas:

BDNF signalling and TrkB receptor biology
CREB transcription factor and gene regulation
Neurogenesis in hippocampus and olfactory bulb
Synaptic plasticity, LTP, and memory consolidation
Neuroinflammation and microglial activation
Neuropeptide receptor pharmacology
BBB penetration and intranasal delivery

Recommended External Reading:

PubMed: BDNF Cognitive Enhancement — Search “BDNF memory LTP”
Neuroscience & Biobehavioral Reviews — Neuropeptide reviews
Brain & Cognition Journal
Russian Journal of Bioorganic Chemistry — Semax/Selank research
Molecular Neurobiology — Mechanism-focused reviews

Explore Neuropeptide Research

Browse our selection of cognitive-enhancing and neuroprotective peptides (Semax, Selank, DSIP, Colivelin, Dihexa), all third-party tested with COAs.

Questions About Neuropeptide Research?

Our support team is available to discuss:

Selecting neuropeptides for your research application
Combining peptides synergistically (e.g., Semax + Selank)
Intranasal administration protocols
Dosing, reconstitution, and storage
Interpreting cognitive and neuroprotection endpoints

Browse

Want to chat?

Social